No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT
Kassandra L. Munger(Harvard University), Alberto Ascherio(Brigham and Women's Hospital), Ludwig Kappos(Novartis (Switzerland)), Christoph Pohl, Frederik Barkhof(Netherlands Institute for Neuroscience), Rupert Sandbrink(Io Therapeutics (United States)), Gilles Edan(Centre National de la Recherche Scientifique), Gustavo Cruz(Düsseldorf University Hospital), David H. Miller(National Hospital for Neurology and Neurosurgery), Mark S. Freedman, Ernst-Wilhelm Radüe(Düsseldorf University Hospital), Kathryn C. Fitzgerald(Johns Hopkins University), Hans-Peter Hartung(The University of Sydney), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 63
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k